Non-Alcoholic Steatohepatitis (NASH) Market Share, Size and Growth Analysis By 2029

The market for non-alcoholic steatohepatitis (NASH) is anticipated to grow significantly, reaching an estimated US$ 24,266.81 million by 2028, up from US$ 1,631.92 million in 2021. This growth represents a remarkable compound annual growth rate (CAGR) of 47.1% from 2021 to 2028.

Several key factors are propelling the expansion of the NASH market. The increasing incidence of NASH, coupled with heightened awareness initiatives, plays a crucial role in this growth. Additionally, the rising number of clinical trials focusing on drug combinations is expected to shape future market trends throughout the forecast period. However, challenges such as the absence of standardized guidelines for diagnosing and managing NASH, along with the withdrawal of certain drugs from clinical trial phases, pose significant obstacles to market advancement.

NASH is a serious condition that can lead to severe liver damage, including extensive scarring and cirrhosis. Non-alcoholic fatty liver disease (NAFLD) is recognized as the most prevalent chronic liver disease worldwide, with NASH representing a progressive form of NAFLD. This condition is increasingly recognized as a leading cause of end-stage liver disease and the need for liver transplants. According to the Global Liver Institute, NASH was declared an epidemic on June 12, 2019, affecting over 115 million individuals, with projections suggesting that 357 million people could be impacted by 2030. Major risk factors for NAFLD and NASH include obesity, type 2 diabetes, and hyperlipidemia, with statistics indicating that over 70% of affected individuals are obese, approximately 75% have type 2 diabetes, and between 20-80% experience hyperlipidemia globally. If untreated, NASH can progress to cirrhosis and liver cancer, significantly increasing the demand for liver transplants.

Data from the American Liver Foundation highlights that NAFLD is the most common chronic liver disease in the United States, with an estimated 25% of adults affected, of which around 20% have NASH, translating to about 5% of the adult population. The NASH Education Program forecasts a 63% increase in NASH prevalence from 2015 to 2030, predicting that NASH will become the leading cause of liver transplants in the U.S. between 2020 and 2025. A report published by the American Association for the Study of Liver Diseases in 2018 utilized Markov modeling to project NAFLD trends through 2030, estimating a 21% rise in NAFLD cases and a 63% increase in NASH cases, leading to prevalence rates of 33.5% and 27% respectively among adults.

Despite the rising prevalence of NASH, it remains a largely under-recognized condition, making early detection vital to mitigate the risk of disease progression and its associated complications. Consequently, the increasing incidence of NASH is a significant driver for the growth of the NASH market.

The NASH market is categorized by product types, including vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the "others" category dominated the market share, while the selonsertib & cenicriviroc segment is projected to experience the fastest CAGR during the forecast period.

When segmented by application, the NASH market is divided into treatment and diagnosis categories. The treatment segment held a larger market share in 2021 and is expected to witness a higher CAGR in the coming years.

In terms of distribution channels, the NASH market is segmented into hospital pharmacies, retail pharmacies, and online providers. The retail pharmacy segment accounted for the largest share in 2021 and is anticipated to register the highest CAGR from 2021 to 2028.

Key secondary sources utilized in the preparation of the NASH market report include the Organization for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), National Health Service (NHS), Centers for Disease Control and Prevention (CDC), Diabetes UK, National Center for Biotechnology Information (NCBI), Korean Diabetes Association (KDA), United Nations (UN) Global Population Prospects, National Statistics Institute, and the World Health Organization (WHO).